earn report chang price
strong pharma perform despit tough comp driven strength
across busi group particularli strong perform ms
cell analysi crosslab consum servic genom
global growth demand spectroscopi gc crosslab
oper leverag mix well impact agil agil
program boost gm
return sharehold mm stock repo
mm dividend mm acquisit close two
announc acquisit pipelin record compani
continu weak china environment food due
reorgan ministri
tariff nois forc action suppli chain product mitig
thesi updat theatric involv last qs print
content gener solid unev result thank
real highlight clearli margin nitpick
core view result solid unspectacular although
easili explain expect food environment soft read
china respect guid manag kept conserv
bia although made issu core ultim
manag team chosen consist promis
deliv frankli fine overreact
team guid time respect
capit alloc encourag uptick activ
key tenet stori formerli trap
cash balanc sheet becom unlock translat ep
thu mind agil thesi gener unchang
good thing expect volatil group post
solid perform potenti nt volatil core growth china
tariff situat eu nois elev rel valuat idiosyncrat
upsid new core driver solid increment elev capit
alloc keep us construct given dynam reiter
outperform rate tweak pt higher
continu next page
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
 rais guidanc vs core prior
 rais vs prior
 rais om bp adjust mm keysight book vs prior
adjust mm keysight bill classifi
 rais ep vs prior
 increas tariff effect earli juli expect neg impact mm
 core report fx hw tw
 strength driven broad base geograph strength particularli china europ strength lsag acg
biopharma strength lsag acg china
 offer strong demand cell analysi molecular spectroscopi icp/m crosslab consum servic
diagnost appli demand genom reagent partnership biz
 china weak environment food continu due reorgan ministri
 dd growth
 dd growth pharma chemic
 slow instrument sale food environment due continu reorg ministri expect temporari
europ flat due tough comp
 exclud nasd biz declin expect quarter core growth would vs includ nasd
 nasd rev batch-bas caus lumpi biz expect return
 dd growth genom strength reagent partnership biz
 driven robust pharma chemic market
 lc/m cell analysi icp/m lead result
 strength america china
 gain across major end-market led dd growth chemic well strong result pharma food
 china led growth region w/ mid-teen growth
increas tariff effect earli juli expect neg impact mm
 initi suppli chain action complet mid-fi expect net annual impact mm exclud
tariff remain place plan aggress reduc effect
 potenti chang price
 adjust suppli chain
howev seen chang custom buy behavior
valuat methodolog base mix discount cash flow analysi rel valuat multipl
risk valuat includ regulatori risk overal market risk well unforeseen event relat individu cover
compani broader sector includ new competit product technolog
laboratori corp america hold
articl articl
time dissemin august et
analyst ross muken luke sergott primarili respons prepar research report attest follow
view opinion render research report reflect person view subject compani issuer part
research analyst compens directli relat specif recommend view research report
